You are here: Industry Insights > Market News > M&As this week: Zhejiang Hisoar Pharmaceutical, tella

Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!

Note: You can unsubscribe from the alerts at any time.

Advertising

New Products

Retatrutide 2381089-83-2

98% Bifida Ferment Lysate

rhSOD (cosmetic grade)

Recombinant humanized collagen

Recombinant Humanized Small-molecule Collagen

Recombinant Humanized Small-molecule Collagen Solution

M&As this week: Zhejiang Hisoar Pharmaceutical, tella

pharmaceufical-technologySeptember 30, 2017

Tag: Zhejiang Hisoar Pharmaceutical , tella

Favorites

Chinese pharmaceutical company Zhejiang Hisoar Pharmaceutical plans to divest a 16.1% stake in a biotechnology company.

The sale is planned to be made to limited partnerships and individuals for CNY144m ($21.8m).

Regenerative and cell medicines developer tella has divested a 44.4% stake in a cell processing facilities consolidated subsidiary.

"Regenerative and cell medicines developer tella has divested a 44.4% stake in a cell processing facilities consolidated subsidiary."

tella has received CNY110m ($0.98m) as consideration from the sale.

Both entities involved in the transaction are based in Japan.

Previous:Deals this week: Mithra, Hainan Haiyao, TherapeuticsMD

Next:GSK’s Benlysta receives Japanese MHLW approval for systemic lupus erythematosus

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

PRNewswireDecember 18, 2024

Seoul 120 hotline has contributed to efficient city operation, according to the Evaluation Report on Worldwide City Hotline Services and Governance Effectiveness (2024) released on Wednesday.

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

PRNewswireDecember 18, 2024

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

PRNewswireDecember 18, 2024

M&As this week: Zhejiang Hisoar Pharmaceutical, tella | Pharmasources.com

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

PRNewswireDecember 19, 2024

Pharus Diagnostics LLC. (PharusDx), announced a significant step forward in the fight against pancreatic cancer. The company is announcing availability of its OncoSweep™ Pancreas Spotlight

M&As this week: Zhejiang Hisoar Pharmaceutical, tella

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

You may like
More>>

M&As this week: Zhejiang Hisoar Pharmaceutical, tella

Related News

Xinhua Silk Road: Evaluation report highlights Seoul 120 hotline for its efficient operation

Gan & Lee Pharmaceuticals Announces U.S. FDA Clearance of the IND application for the innovative Bi-weekly GLP-1RA GZR18 Injection, Bofanglutide, with chronic weight management Indication (A Phase 2 h

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Pr

Pharus Diagnostics LLC Announces Validation of a Laboratory-Developed Test for Early Pancreatic Cancer Detection

You may likeMore>>

You may like
More>>